Table of Content

Number of Pages: 81 **Published: July, 2020**

- Non-VEGF targets to act upstream to address all oxidative pathways with potential to reduce treatment burden, improve visual outcomes, a solution to the sub-optimal efficacy of current treatment
- Potential of gene therapy to transform the DME treatment landscape -one-time treatment for the patients who have demonstrated a very strong dependence on frequent anti-VEGF treatments
- Novel oral and topical therapies could transform the standard of care with non-invasive and prophylactic treatment
- Sustained drug delivery treatment to address the need for frequent intravitreal injections

CHAPTER 6: AMIDST BIOSIMILARS, HIGH-COST DME DRUG MARKET IN THE US ESTIMATE TO GROW RAPIDLY WITH THE ENTRY OF DRUGS WITH MORE DURABILITY, NON-INVASIVE TREATMENT OPTIONS AND DOWN THE LINE WITH THE ENTRY OF GENE THERAPY

- Anti-VEGFs leads the current DME market due to its proven efficacy compared to steroids
- Off-label use of Avastin and Triamcinolone acetonide, indicative of price sensitivity influence on prescription and insurance coverage
- Current market landscape of anti-VEGF's and steroids and potential pipeline compounds to drive market growth in the DME sector
- Impact of biosimilars in the current landscape